Drotrecogin alpha (activated) in neonatal septic shock

Scandinavian Journal of Infectious Diseases

Volumn 37, Issue 4, 2005, Pages 306-308

  Frommhold, David ^a   Birle, Alexandra ^a   Linderkamp, Otwin ^a   Zilow, Eugen P ^a   Pöschl, Johannes M B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; AMPICILLIN; CD14 ANTIGEN; CEFOTAXIME; CREATININE; D DIMER; DEXAMETHASONE; DOPAMINE; DROTRECOGIN; FIBRINOGEN; HEPARIN; NETILMICIN; NORADRENALIN; OXYGEN; PHENOBARBITAL;

APNEA; ARTICLE; BACTERIAL MENINGITIS; BLOOD PRESSURE MONITORING; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CONTINUOUS INFUSION; CREATININE URINE LEVEL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; ECHOGRAPHY; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; GENERAL CONDITION DETERIORATION; GENERAL CONDITION IMPROVEMENT; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; INFANT; LEUKOCYTE COUNT; MALE; MONOTHERAPY; MULTIPLE ORGAN FAILURE; NEWBORN DISEASE; OLIGURIA; SEPTIC SHOCK; STREPTOCOCCUS AGALACTIAE; SUBARACHNOID SPACE; TONIC CLONIC SEIZURE; TREATMENT OUTCOME;

ANTI-INFECTIVE AGENTS; HUMANS; INFANT, NEWBORN; MALE; MENINGITIS, PNEUMOCOCCAL; PROTEIN C; RECOMBINANT PROTEINS; SHOCK, SEPTIC; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 17444383118     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540510031412     Document Type: Article

References (21)

1. Grey ST, Tsuchida A, Hau H, Orthner CL, Salem HH, Hancock WW. Selective inhibitory effects of the anticoagulant activated protein C on the responses of human mononuclear phagocytes to LPS, IFN-[gamma], or phorbol ester. J Immunol 1994;153:3664-72.
2. Yan SB, Grinnell BW. Antithrombotic and anti-inflammatory agents of the protein C anticoagulant pathway. Ann Rep Med Chem 1994;11:103-12.
3. Bajzar L, Nesheim M, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996;88:2093-100.
4. Faust SN, Levin M, Harrison OB, Goldin RD, Lockhart MS, Kondaveeti S, et al. Dysfunction of endothelial protein C activation in severe meningococcal sepsis. N Engl J Med 2001;345:408-16.
5. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
6. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al. Effects of drotrecogin alpha (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003;3:834-40.
7. Bernard GR, Macias WL, Joyce DE, Williams MD, Bailey J, Vincent JL. Safety assessment of drotrecogin alpha (activated) in the treatment of adult patients with severe sepsis. Crit Care 2003;7:155-63.
8. Bachli EB, Vavricka SR, Walter RB, Leschinger MI, Maggiorini M. Drotrecogin alpha (activated) for the treatment of meningococcal purpura fulminans. Intensive Care Med 2003;29:337.
9. Dhainaut JF, Yan SB, Joyce DE, Pettila V, Basson B, Brandt JT, et al. Treatment effects of drotrecogin alpha (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost 2004;2: 1924-33.
10. Dhainaut JF, Yan SB, Claessens YE. Protein C/activated protein C pathway: overview of clinical trial results in severe sepsis. Crit Care Med 2004;32[Suppl]:S194-201.
11. Dalton HJ. Recombinant activated protein C in paediatric patients. Pediatr Infect Dis J 2003;22:743-5.
12. Weiss KD. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alpha (activated) in children with severe sepsis. Pediatrics 2004;113:134.
13. Barton P, Kalil AC, Nadel S, Goldstein B, Okhuysen-Cawley R, Brilli RJ, et al. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alpha (activated) in children with severe sepsis. Pediatrics 2004;113:7-17.
14. Giroir BP. Recombinant human activated protein C for the treatment of severe sepsis: is there a role in paediatrics? Curr Opin Pediatr 2003;15:92-6.
15. Grunwald U, Kruger C, Westermann J, Lukowsky A, Ehlers M, Schutt C. An enzyme-linked immunosorbent assay for the quantification of solubilized CD14 in biological fluids. J Immunol Methods 1992;155:225-32.
16. Blanco A, Solis G, Arranz E, Coto GD, Ramos A, Telleria J. Serum levels of CD14 in neonatal sepsis by Gram-positive and Gram-negative bacteria. Acta Paediatr 1996;85:728-32.
17. Pöschl JMB, Hellstern G, Ruef P, Bauer J, Linderkamp O. Ophthalmia neonatorum caused by group B Streptococcus. Scand J Infect Dis 2002;34:921-2.
18. Martinot A, Leclerc F, Cremer R, Leteurtre DS, Fourier C, Hue V. Sepsis in neonates and children: definitions, epidemiology, and outcome. Pediatr Emerg Care 1997;13:227-81.
19. Henneke P, Takeuchi O, van Strijp JA, Guttormson HK, Smith JA, Schromm AB, et al. Novel engagement of CD14 and muliptle Toll-like receptors by group B Stretococci. J Immunol 2001;169:3970-7.
20. De Keijn ED, de Groot R, Hack E, Mulder PGH, Engl W, Moritz B, et al. Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: a randomized, double blinded, placebo-controlled, dose-finding study. Crit Care Med 2003;31:1839-47.
21. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russel JA, Freebairn RC, et al. PROWESS Sepsis Study Group: Drotrecogin alpha (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003;90: 642-53.